Navigation Links
Blood vessel forming potential of stem cells from human placenta and umbilical cord blood
Date:7/19/2012

Tampa, Fla. (July 19, 2012) A study comparing whether endothelial colony-forming cells (ECFCs) derived from human placenta or those derived from human umbilical cord blood are more proliferative and better for forming new blood vessels has found that ECFCs derived from human placenta are more vasculogenic.

The study, carried out by researchers at the Indiana School of Medicine, is published in a recent issue of Cell Medicine [2(3)] and is freely available on-line at: http://www.ingentaconnect.com/content/cog/cm.

"Circulating ECFCs isolated from umbilical cord blood and those isolated from human placenta are phenotypically identical and have equivalent proliferative potential," said study lead author Michael P. Murphy, MD of the Indiana University's Department of Surgery. "After transplantation, the circulating placenta-derived ECFCs formed significantly more blood vessels in vivo than the ECFCs derived from umbilical cord blood, indicating not only that there are inherent functional differences between resident and circulating ECFC populations, but that the placenta-derived cells are more vasculogenic."

Umbilical cord blood and the extra-embryonic membranes of placenta are ideal sources of progenitor cells, said the researchers, because the tissues are discarded as medical waste and ethical concerns facing embryonic stem cells are avoided. The quantity of cells that can be derived from placenta, however, is much greater than the amount that can be derived from umbilical cord blood, making the placenta the more abundant source.

They concluded that the placenta represents an abundant source of ECFCs that could provide a therapeutic dose of cells.

"The potential volume of placenta-derived ECFCs that can be harvested from a single placenta would provide a sufficient dose of cells without the necessity of expansion," noted Murphy.

According to the researchers, the role of circulating ECFCs has yet to be determined, yet circulating mature endothelial cells are rarely found in normal, healthy individuals as they are markers of vascular damage, remodeling and dysfunction.

"We envision that placenta-derived ECFCs may provide some benefit in neonatal cerebral ischema or can be used for tissue banking for future and be useful in treating cardiovascular disease," said Murphy and his colleagues.


'/>"/>

Contact: David Eve
cellmedicinect@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. True blood: SLU scientist investigates clotting factors
2. Dinosaurs were warm-blooded reptiles
3. Blood-brain barrier building blocks forged from human stem cells
4. Boosting blood system protein complex protects against radiation toxicity
5. New study: Snacking on raisins significantly reduces overall post-meal blood sugar levels
6. Manipulating chromatin loops to regulate genes may offer future treatments for blood diseases
7. Common genetic mutation increases sodium retention, blood pressure
8. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
9. New microscope uses rainbow of light to image the flow of individual blood cells
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Leeches are DNA bloodhounds in the jungle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/7/2017)... WARSAW, Ind. , Feb. 7, 2017 ... global leader in musculoskeletal healthcare, will present at the ... Lotte New York Palace Hotel on Wednesday, February 15, ... A live webcast of the presentation can be accessed ... for replay following the conference via Zimmer Biomet,s Investor ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... YORK , Feb. 20, 2017 This report ... by the following Product Types: Xylanase, Amylase, Cellulase, and Others. ... Canada , Japan , ... Latin America , and Rest of World. ... Annual estimates and forecasts are provided for the period ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, ... with peritoneal dialysis, announced today that it has published the result of its ... Peritoneal Dialysis International (PDI), the official Journal of the International Society for ...
(Date:2/18/2017)... Kurzlehrgang mit Fokus auf ... Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen dar   ... ... Yoav Peretz , Scientific Director bei ImmuneCarta, einen ... zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im Rahmen ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a ... announce development of a novel system for quantitative ... with the University of Rochester (NY, USA) and ... The new system is able to accurately quantify ... HER2 (Human epidermal growth factor receptor-2) in clinical ...
Breaking Biology Technology: